SCHEMBL15535916

SCHEMBL15535916

CC(C)(C)OC(=O)NC(C(=O)O)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MAPK1 P28482 1/20 0.48
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.41
EPHX2 P34913 2/20 0.39
GAA P10253 1/20 0.39
CACNA1H O95180 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
ALOX15 P16050 1/20 0.36
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27978333 1.00 KMT2A (0.48) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL8299304 1.00 KMT2A (0.48) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL30170170 0.94 KMT2A (0.41) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL18631592 0.94 KMT2A (0.41) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL24815908 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL2110140 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL2549745 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL27218008 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL8271718 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1
SCHEMBL27218038 0.86 KMT2A (0.39) KMT2AMEN1MAPK1HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759075-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP disclosed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN disclosed
US-20230312571-A1 RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) 2023-10-05 US disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US disclosed
CN-112824398-B Immunomodulator 成都先导药物开发股份有限公司 2022-10-21 CN disclosed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP disclosed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN disclosed
CN-112341439-A Immunomodulator 成都先导药物开发股份有限公司 2021-02-09 CN disclosed
CN-112041301-A Compounds having iron death inducing activity and methods of use thereof 费罗治疗公司 2020-12-04 CN disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed
US-9416105-B2 Process for preparation of saxagliptin and its hydrochloride salt AMNEAL PHARMACEUTICALS LLC (US) 2016-08-16 US disclosed
US-20160194282-A1 A Process For Preparation Of Saxagliptin And Its Hydrochloride Salt AMNEAL PHARMACEUTICALS LLC 2016-07-07 US disclosed
US-9199933-B2 Process for preparation of (1S, 3S, 5S)-2-[(2S)-2-amino-2-(3-hydroxy-I-adamantyl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile Davuluri, Ramamohan Rao (IN) 2015-12-01 US disclosed
US-20150112084-A1 PROCESS FOR PREPARATION OF (IS, 3S, 5S)-2-[(2S)-2-AMIN0-2-(3-HYDROXY-l-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0] HEXANE-3-CARBONITRILE DAVULURI, RAMAMOHAN RAO (IN) 2015-04-23 US disclosed
WO-2015031595-A1 A PROCESS FOR PREPARATION OF SAXAGLIPTIN AND ITS HYDROCHLORIDE SALT AMNEAL PHARMACEUTICALS LLC (US) 2015-03-05 WO disclosed
US-20150038672-A1 Modular Imaging Agents Containing Amino Acids and Peptides ROCHESTER INSTITUTE OF TECHNOLOGY (US) 2015-02-05 US disclosed
WO-2013175395-A2 IMPROVED PROCESS FOR PREPARATION OF SAXAGLIPTIN AND ITS SALTS DR. REDDYS LABORATORIES LIMITED (IN) 2013-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038672-A1 Modular Imaging Agents Containing Amino Acids and Peptides SLC43A1, TAP1, TTR KMT2A 1695/4885MEN1 91/4885MAPK1 1668/4885
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 KMT2A 2510/4885MEN1 1772/4885MAPK1 3912/4885
US-20160194282-A1 A Process For Preparation Of Saxagliptin And Its Hydrochloride Salt DPP4, SLC5A1, DPP9 KMT2A 2763/4885MEN1 2544/4885MAPK1 334/4885
US-20230312571-A1 RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF VIP, PREP, PRAP1 KMT2A 3623/4885MEN1 1707/4885MAPK1 998/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB KMT2A 2943/4885MEN1 3968/4885MAPK1 1188/4885
US-20150112084-A1 PROCESS FOR PREPARATION OF (IS, 3S, 5S)-2-[(2S)-2-AMIN0-2-(3-HYDROXY-l-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0] HEXANE-3-CARBONITRILE DPP4, DPP3, DPP9 KMT2A 4548/4885MEN1 1723/4885MAPK1 1324/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 KMT2A 2475/4885MEN1 1681/4885MAPK1 3769/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI KMT2A 3236/4885MEN1 4010/4885MAPK1 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.